-=Teva Pharma (TEVA) reported earnings on Thur 1 Nov 2018 (b/o)

• Topped Q3 earnings expectations by $0.14 on revs that fell 19.4% year/year to fall in-line with consensus; raised FY18 EPS guidance above consensus while raising the low end of its FY18 revs target; co indicated that revenue decline was connected largely to loss of revenues following certain divestitures as well as price erosion and competition to COPAXONE arising from shifts in the U.S. generics business, though co management notes that COPAXONE "continues to maintain its market share" despite revenue decrease; AUSTEDO saw "strong growth."

Teva Pharma beats by $0.14, reports revs in-line; raises FY18 EPS above consensus, tweaks rev, in-line

Reports Q3 (Sep) earnings of $0.68 per share, $0.14 better thanthe S&P Capital IQ Consensus of $0.54; revenues fell 19.4% year/year to $4.53 bln vs the $4.54 bln S&P Capital IQ Consensus, or 18% in local currency terms, compared to the third quarter of 2017, mainly due to generic competition to COPAXONE, price erosion in our U.S. generics business and loss of revenues following the divestment of certain products and discontinuation of certain activities.

Co issues guidancefor FY18, raises EPS to $2.80-2.95 from $2.55-2.80, excluding non-recurring items, vs. $2.78 S&P Capital IQ Consensus; sees FY18 revs of $18.6-19.0 bln from $18.5-19.0 bln vs. $18.85 bln S&P Capital IQ Consensus.